Research programme: monoclonal antibody biosimilars - PharmaPraxis/PlantForm Corporation

Drug Profile

Research programme: monoclonal antibody biosimilars - PharmaPraxis/PlantForm Corporation

Alternative Names: Bevacizumab biosimilar

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator PlantForm - PharmaPraxis (JV)
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Immunological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Brazil (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in Brazil (Parenteral)
  • 20 Jun 2014 PharmaPraxis and PlantForm establish a joint venture to develop biosimilar monoclonal antibodies in Brazil for the treatment of cancer and immunological disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top